イスラエル's Teva Pharm 利益（をあげる） 落ちるs いっそう少なく than 推定する／予想するd, CFO to leave
By Tova Cohen and Steven Scheer
TEL AVIV, Aug 7 (Reuters) - Teva 製薬の 産業s 報告（する）／憶測d a smaller-than-推定する／予想するd 減少（する） in second-４半期/4分の1 利益（をあげる） on Wednesday and said its 長，指導者 財政上の officer was leaving the company.
にもかかわらず the （警官の）巡回区域，受持ち区域, its 株 were 負かす／撃墜する 4% in 早期に 貿易（する） on the NYSE on 関心s over 現在進行中の opioid litigation in the 部隊d 明言する／公表するs and over the pace of 支払う／賃金ing 負かす／撃墜する its 抱擁する 負債. It 株 have fallen 58% so far in 2019.
Teva had 合法的な 解決／入植地s and loss contingencies of $646 million in the ４半期/4分の1. These おもに 関係のある to an $85 million 解決／入植地 paid in litigation brought by the Oklahoma 弁護士／代理人／検事 general and an 概算の 準備／条項 made for 確かな other opioid 事例／患者s they may settle in the 未来.
The company said the Oklahoma 解決／入植地, 存在 the first one, （機の）カム with a 賞与金.
"For 戦術の 推論する／理由s we みなすd that it was best to settle there," 大統領 Kare Schultz told Reuters. "That does no way mean that we would be 利益／興味d or willing to settle for the same 量 with all the other 明言する／公表するs."
He said Teva 否定するs any 義務／負債 and does not see any 不品行／姦通 on its part in the opioid 事例／患者s or in a separate price 直す／買収する，八百長をするing 調査 存在 carried out by the 司法省.
Danish-born Schultz, who joined Teva in November 2017, said he was surprised by the "political nature" of the U.S. opioid 危機 and said he would stay at least till the end of his five-year 契約.
"I'm not the 肉親，親類d of guy who やめるs unless the 職業 is done. So of course, I will see it through. If I have to stay longer to see it through I will do it," he told a 会議／協議会 call.
The world's largest generic drugmaker earned 60 cents per diluted 株 除外するing one-time items in the April-June ４半期/4分の1, 負かす／撃墜する from 78 cents a year earlier.
歳入 fell 8% to $4.34 billion おもに 予定 to generic 競争 to its 多重の sclerosis 麻薬 Copaxone and lower 歳入s from cholester ol 治療 Treanda.
分析家s had 予測（する） Teva would earn 57 cents a 株 ex-items on 歳入 of $4.25 billion, によれば I/B/E/S data from Refinitiv.
Schultz said Teva was on 跡をつける to 会合，会う its 的s of a two-year 再編成 計画（する）. "Based on our good results for the first half of the year we are 再確認するing our 十分な year 指導／手引," he said.
Teva has 減ずるd its spending by $2.7 billion since 始めるing the 再編成 last year and said it was on 跡をつける to 削減（する） spending by $3 billion by the end of this year.
Teva's 負債 負担 shrunk to $28.7 billion by the end of June and 分析家s are 関心d over the ability to 支払う／賃金 it 負かす／撃墜する.
Its "in-line ４半期/4分の1 is likely insufficient to 緩和する the 重要な 近づく-称する，呼ぶ／期間／用語 投資家 関心 of てこ入れ／借入資本 and 負債 paydown against the 背景 of 現在進行中の opioid litigation," said Citi 分析家 Liav Abraham.
For 2019, the company had 予測（する） adjusted EPS of $2.20-$2.50 and 歳入 of $17.0-$17.4 billion. 分析家s are 予測（する）ing EPS of $2.37 on 歳入 of $17.14 billion.
Teva said Michael McClellan had decided to step 負かす／撃墜する as CFO 予定 to personal 推論する／理由s 要求するing him to be 位置を示すd 近づく his family. Teva has begun a search for a new CFO and McClellan is 推定する／予想するd to remain in his 役割 until after the group's third ４半期/4分の1 results.
The 告示 McClellan's 出発 "is ありそうもない to 緩和する 投資家s' 関心s regarding the company´s 負債 paydown 戦略," Abraham said in a 公式文書，認める to （弁護士の）依頼人s.
In the second ４半期/4分の1, North American sales of migraine 麻薬 Ajovy, 開始する，打ち上げるd last September, were $23 million, while sales of Huntington's 治療 Austedo more than 二塁打d to $96 million.
The world's largest generic drugmaker is counting on Ajovy and Austedo to help 生き返らせる its fortunes after 再編成 to 取り組む a 負債 危機.
Schultz said he did not 推定する／予想する that if the 部隊d 明言する／公表するs decides to 輸入する generic 麻薬s it would be a 脅し to Teva's pricing as U.S. generic 麻薬 prices have already fallen はっきりと. (Additio nal 報告（する）／憶測ing by Carl O'Donnell and Ari Rabinovitch Editing by Jane Merriman and David Evans)
